相关临床试验
23
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
21
91.3%
招募中
2
8.7%
暂无批准数据
- CASI Pharmaceuticals reported promising interim results from its Phase 1 study of CID-103, an anti-CD38 monoclonal antibody, achieving the primary efficacy endpoint in 73% of immune thrombocytopenia patients. - The study demonstrated a manageable safety profile with only two Grade 3 treatment-related events and no dose-limiting toxicities across dose levels from 30 mg to 900 mg. - Complete response was achieved in 75% of responding patients, with platelet improvements observed as early as one week post-dose, supporting further development in autoimmune disorders. - The results provide clinical proof of concept for CID-103's mechanism of action, showing reduction in anti-platelet antibodies and immune cells consistent with the observed therapeutic response.
- CASI Pharmaceuticals' stock surged 57.2% to $2.028 after the FDA cleared its IND application for CID-103, an anti-CD38 monoclonal antibody targeting kidney transplant rejection. - The Phase 1 trial will evaluate CID-103 in adults with active and chronic active renal allograft antibody-mediated rejection, addressing an $800 million to $1.2 billion unmet medical need. - Trading volume spiked 2,043% to 62.9 million shares, indicating strong institutional interest in the regulatory milestone. - The FDA clearance positions CID-103 as a potential best-in-class therapy for antibody-mediated rejection, where current treatments face safety limitations.
- CASI Pharmaceuticals appointed industry veteran David Cory as CEO to lead the U.S. operations and focus on advancing CID-103, a potential best-in-class anti-CD38 monoclonal antibody. - CID-103 is currently dosing patients in a multi-center Phase 1/2 study for chronic immune thrombocytopenia (ITP) and has an IND application filed for renal allograft antibody-mediated rejection. - Cory brings over 30 years of biotech experience, having raised over $1 billion in capital markets and led multiple company exits totaling approximately $9 billion in acquisitions. - The leadership change positions CASI to concentrate resources on maximizing the therapeutic potential of CD38 targeting for organ transplant rejection and autoimmune diseases.
- CASI Pharmaceuticals will host a live conference call and webcast on May 21, 2025, to provide updates on its business operations and clinical pipeline developments. - The biopharmaceutical company is focused on developing therapeutics for hematology oncology, organ transplant rejection, and autoimmune diseases, with operations spanning China, the United States, and globally. - CASI is currently navigating legal challenges related to key pipeline products EVOMELA® and CNCT19, while advancing CID-103 for antibody-mediated rejection in organ transplantation.
- CASI Pharmaceuticals has dosed the first patient in a Phase 1/2 trial of CID-103 for chronic Immune Thrombocytopenia (ITP) in China. - CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody targeting a unique epitope, showing promising preclinical results. - The trial aims to evaluate the safety and tolerability of CID-103 in adult ITP patients, providing dose-response data. - This milestone marks progress for ITP patients with limited options and may guide CID-103's development for other autoimmune diseases.
- The FDA has placed a clinical hold on CASI Pharmaceuticals' CID-103, an anti-CD38 monoclonal antibody, halting its clinical trial. - The hold was initiated due to unspecified reasons, and CASI Pharmaceuticals is currently seeking clarification from the FDA regarding the concerns. - CID-103 is being developed for the treatment of multiple myeloma and other hematological malignancies, representing a potential setback for the company's pipeline. - CASI Pharmaceuticals is committed to addressing the FDA's concerns and working towards the resumption of the clinical trial as soon as possible.
